For a prostate cancer patient who is a kidney transplant recipient, should I use conventional 72 Gy in 36 fractions or a moderate hypofractionated schedule (e.g., 60 Gy/20 fx or 70 Gy/28 fx) with image‑guided IMRT/VMAT?

Moderate Hypofractionation is the Recommended Approach for Kidney Transplant Recipients

For a prostate cancer patient who is a kidney transplant recipient, you should use moderate hypofractionation with 60 Gy in 20 fractions or 70 Gy in 28 fractions delivered via image-guided IMRT/VMAT, rather than conventional 72 Gy in 36 fractions. 1, 2

Evidence-Based Rationale for Moderate Hypofractionation

The 2024 EAU-EANM-ESTRO-ESUR guidelines provide a strong recommendation for moderate hypofractionation (60 Gy/20 fx in 4 weeks or 70 Gy/28 fx in 6 weeks) using IMRT/VMAT plus IGRT for intermediate-risk prostate cancer. 1 This recommendation is supported by high-quality randomized trial evidence demonstrating:

• Superior biochemical control: The 72 Gy in 2.4 Gy fractions (biologically equivalent to 85 Gy conventional) achieved significantly fewer treatment failures (10.7% vs 15.4% at 8 years, P=0.036) compared to conventional fractionation. 3

• Excellent long-term outcomes: The 70 Gy/28 fraction schedule demonstrates 10-year biochemical relapse-free survival of 88% for low-risk, 78% for favorable intermediate-risk, and 71% for unfavorable intermediate-risk disease, with only 2% cumulative grade ≥3 GU toxicity and 1% GI toxicity. 4

• Comparable safety profile: Post-prostatectomy moderate hypofractionation (62.5 Gy in 25 fractions) shows maximal acute GU toxicity of grade 2 in only 8% and maximal late GU toxicity of grade 3 in 1%, with no severe toxicity. 5

Mandatory Technical Requirements for Safe Delivery

Daily image-guided radiotherapy (IGRT) is absolutely essential when delivering hypofractionated regimens to ensure accurate targeting and minimize toxicity. 1, 2 Acceptable IGRT modalities include:

• CT-based daily imaging
• Ultrasound localization
• Implanted fiducial markers with kV or CBCT imaging
• Electromagnetic tracking systems 2

IMRT or VMAT must be employed—three-dimensional conformal techniques are inadequate and significantly increase toxicity risk. 2 The planning must include:

• At least two dose-volume constraint points for rectum (one high-dose, one mid-dose)
• At least two dose-volume constraint points for bladder (one high-dose, one mid-dose)
• Urethral planning risk volume (2 mm expansion) to protect this structure 2

Why Ultrahypofractionation is Contraindicated

Do not use ultrahypofractionation (5-7 fractions) in this patient. 2, 6 The evidence is clear on multiple contraindications:

• Insufficient evidence: Robust data supporting ultrahypofractionation in post-prostatectomy settings is lacking. 2

• Prior urethral stricture: Even when resolved, this elevates baseline urinary toxicity risk and argues strongly against higher per-fraction doses. 2

• Transplant kidney considerations: The kidney transplant status creates additional organ-at-risk constraints that are more safely managed with moderate hypofractionation's lower per-fraction doses. 2

• Absolute contraindications present: If the patient has any history of pelvic irradiation, active inflammatory bowel disease, or permanent catheter, ultrahypofractionation is absolutely contraindicated. 6

Specific Dosing Recommendations

Prescribe 60-70 Gy in 20-28 fractions to the prostate or prostatic fossa, depending on whether this is definitive or post-operative treatment. 1, 2 The two validated schedules are:

• 60 Gy in 20 fractions (3 Gy/fraction) over 4 weeks 1
• 70 Gy in 28 fractions (2.5 Gy/fraction) over 6 weeks 1

Both schedules have demonstrated equivalent efficacy and toxicity profiles in high-quality randomized trials. 3, 4

Critical Pitfalls to Avoid

Do not proceed with treatment if transplant kidney dose constraints cannot be satisfied. 2 In this scenario, you must either:

• Consider alternative treatment modalities (surgery, brachytherapy)
• Revert to conventional fractionation with tighter margins
• Adjust beam angles to minimize kidney exposure 2

Verify dose-volume histogram compliance before treatment initiation. 2 Specifically confirm:

• Rectal V65Gy ≤15% (for the 70 Gy/28 fx schedule, this reduces late GI toxicity from 12.6% to 8.6%) 3
• Bladder mean dose minimized through VMAT optimization 7
• Transplant kidney maximum dose well below tolerance 2

Do not use 3D conformal techniques—the dosimetric advantages of IMRT/VMAT are essential for adequate organ sparing, particularly with the added complexity of a transplant kidney. 2, 7

Patient-Specific Eligibility Confirmation

Before proceeding, confirm the patient does not have:

• Active inflammatory bowel disease (absolute contraindication) 6
• Permanent indwelling Foley catheter (absolute contraindication) 6
• Very low bladder capacity (relative contraindication requiring careful consideration) 6
• Active urethral pathology (relative contraindication; resolved stricture is acceptable) 2

The kidney transplant itself is not a contraindication to moderate hypofractionation, but requires meticulous treatment planning to respect transplant kidney dose constraints. 2